Mar112020UncategorizedCategory: UncategorizedBy Charlotte Maddalena11 March 2020 Author: Charlotte Maddalena Post navigationPreviousPrevious post:First patient treated with anti-CD39 mAb IPH5201 on OREGA’s 10-year anniversary dayNextNext post:Three new projects supported by our FoundationRelated PostsPublication: dispensing temozolomide using KIMOZO or Temodal capsules mixed with food30 September 2022SIOP 2022, Barcelona, Spain: September 28-October 1, 202223 September 2022Organisation Inter Régionale Hémato-Onco pédiatrique14 September 2022Five new projects supported by our Foundation5 July 2022First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®22 June 2022ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspension9 June 2022
Publication: dispensing temozolomide using KIMOZO or Temodal capsules mixed with food30 September 2022
First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®22 June 2022
ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspension9 June 2022
